A nanosomal formulation of paclitaxel, for Kaposi's sarcoma and skin cancers
Dermos™ is a topical treatment for AIDS associated Kaposi's sarcoma (AIDS-KS) and other skin cancers as well as proliferative diseases of the skin utilizing a nanosomal formulation of a potent anticancer drug.
Current Therapies for Treating Kaposi's Sarcoma and Their Side Effects
Liposomal formulations of daunorubicin and doxorubicin have been approved by the FDA for first-line and second-line systemic treatment of AIDS-KS. Liposomes are microscopic vesicles of phospholipid bilayers comprised of single or multiple lipid bilayers.
Paclitaxel, a unique anti-mitotic agent, has been approved by the FDA for systemic application in metastatic cases of breast cancer and refractory cases of ovarian cancer, and AIDS-KS.
These three drugs, while being very effective, are burdened by systemic toxicities such as neutropenia, myelosuppression, alopecia, nausea and vomiting.
Topical Formulation for Treating Kaposi's Sarcoma
A topical formulation of an antineoplastic drug that is effective against visual and subcutaneous Kaposi's sarcoma will reduce the systemic use of these drugs, minimizing blood toxicity levels and improving a patient's quality of life.
Nanosomes are ideal vehicles for the topical delivery of antineoplastic agents. Nanosomes™ are small, uniform liposomes that are less than one nanometer in diameter.
Dermos™ for the Treatment of AIDS-KS as Developed by:
Dermos™ - In Vitro Characterization
To characterize the early steps accompanying apoptosis, KS cells were monitored by 3D epifluorescence confocal microscopy 48 hours after treatment with the topical preparation. Cells treated with PBS showed defined normal nucleoli. In contrast, KS Y-1 cells treated with the topical formulation exhibited overall induced reduction in cell size as well as diffuse staining and clumping of chromatin which is consistent with apoptosis.
Dermos™ - In Vivo Efficacy
Current therapies for Kaposi's sarcoma, while being very effective, are burdened by systemic toxicities such as neutropenia, myelosuppression, alopecia, nausea and vomiting. A topical formulation that is effective against visual and subcutaneous Kaposi's sarcoma would reduce the systemic use of these drugs, minimizing blood toxicity levels and improving a patient's quality of life.
The Dermos™ formulation with other active ingredients will find utility in melanoma, other types of skin cancers and proliferative diseases of the skin such as alopecia.
We are seeking strategic corporate partners to continue the development of Dermos™ for melanoma and other cancers of the skin.